Immunotherapy
Researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have found that immunotherapy together with a new experimental cancer drug could offer a new way of treating patients with aggressive brain cancers.
Early results from a Phase I clinical trial, which were presented at the American Association of Cancer Research (AACR) Annual Meeting on Saturday, found particular signs of effectiveness in patients with defects in a key gene called PTEN.
